Patents by Inventor Douglas James Riexinger

Douglas James Riexinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PAR4 agonist peptides
    Patent number: 9303065
    Abstract: The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: April 5, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael G. Kornacker, Claudio Mapelli, Douglas James Riexinger
  • PAR4 AGONIST PEPTIDES
    Publication number: 20150158910
    Abstract: The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.
    Type: Application
    Filed: November 26, 2014
    Publication date: June 11, 2015
    Inventors: Michael G. KORNACKER, Claudio Mapelli, Douglas James Riexinger
  • PAR4 agonist peptides
    Patent number: 8927688
    Abstract: PAR4 agonist peptides are disclosed. These peptides are useful for developing robust PAR4 receptor assays.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: January 6, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael G. Kornacker, Claudio Mapelli, Douglas James Riexinger
  • PAR4 AGONIST PEPTIDES
    Publication number: 20130289238
    Abstract: The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays.
    Type: Application
    Filed: April 24, 2013
    Publication date: October 31, 2013
    Inventors: Michael G. Kornacker, Claudio Mapelli, Douglas James Riexinger
  • N-terminally modified GLP-1 receptor modulators
    Patent number: 7960349
    Abstract: The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that may stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: June 14, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: William R. Ewing, Claudio Mapelli, Douglas James Riexinger, Ving G. Lee, Richard B. Sulsky, Yeheng Zhu
  • Sustained release glp-1 receptor modulators
    Publication number: 20100022457
    Abstract: The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.
    Type: Application
    Filed: November 8, 2006
    Publication date: January 28, 2010
    Inventors: Feng Qian, William R. Ewing, Claudio Mapelli, Douglas James Riexinger, Ving G. Lee, Richard B. Sulsky, Yeheng Zhu, Tasir Shamsul Haque, Rogelio L. Martinez, Vijay Naringrekar, Nina Ni, Lori S. Burton
  • Sustained release GLP-1 receptor modulators
    Patent number: 7534763
    Abstract: The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: May 19, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Feng Qian, William R. Ewing, Claudio Mapelli, Douglas James Riexinger, Ving G. Lee, Richard B. Sulsky, Yeheng Zhu, Tasir Shamsul Haque, Rogelio L. Martinez, Vijay Naringrekar, Nina Ni, Lori S. Burton
  • HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
    Publication number: 20080242593
    Abstract: The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
    Type: Application
    Filed: March 3, 2008
    Publication date: October 2, 2008
    Inventors: William R. Ewing, Claudio Mapelli, Richard B. Sulsky, Tasir Shamsul Haque, Ving G. Lee, Douglas James Riexinger, Rogelio L. Martinez, Yeheng Zhu
  • Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions
    Patent number: 7417028
    Abstract: The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: August 26, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: William R. Ewing, Claudio Mapelli, Richard B. Sulsky, Tasir Shamsul Haque, Ving G. Lee, Douglas James Riexinger, Rogelio L. Martinez, Yeheng Zhu
  • Beta secretase exosite binding peptides and methods for identifying beta secretase modulators
    Patent number: 7314726
    Abstract: The present invention provides peptides that specifically bind to BACE at a newly discovered exosite. The invention also provides methods for identifying peptides that bind to a BACE exosite. The invention further provides methods for identifying compounds that bind to a BACE exosite and modulate BACE activity. In another aspect, the invention provides methods for treating or preventing neurodegenerative disorders such as Alzheimer's disease by administering compounds that bind to a BACE exosite and modulate BACE activity.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: January 1, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael G. Kornacker, Robert A. Copeland, Joseph Hendrick, Zhihong Lai, Claudio Mapelli, Mark Richard Witmer, Jovita Marcinkeviciene, William Metzler, Ving Lee, Douglas James Riexinger
  • Beta secretase exosite binding peptides and methods for identifying beta secretase modulators
    Publication number: 20040121412
    Abstract: The present invention provides peptides that specifically bind to BACE at a newly discovered exosite. The invention also provides methods for identifying peptides that bind to a BACE exosite. The invention further provides methods for identifying compounds that bind to a BACE exosite and modulate BACE activity. In another aspect, the invention provides methods for treating or preventing neurodegenerative disorders such as Alzheimer's disease by administering compounds that bind to a BACE exosite and modulate BACE activity.
    Type: Application
    Filed: October 15, 2003
    Publication date: June 24, 2004
    Inventors: Michael G. Kornacker, Robert A. Copeland, Joseph Hendrick, Zhihong Lai, Claudio Mapelli, Mark Richard Witmer, Jovita Marcinkeviciene, William Metzler, Ving Lee, Douglas James Riexinger